Verastem, Inc.
VSTMNext catalyst
Defactinib
Pancreatic Adenocarcinoma
Get an email about VSTM's next catalysts
Track Verastem (VSTM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 6 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
7 upcoming, 2 past
VSTM Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.44 | FQ end Sep/2026 | Call: amc
Defactinib Phase 2 Est. Readout
Estimated primary completion for Defactinib trial (NCT05787561) in Mesonephric Gynecologic Cancer. Topline data typically follows completion by weeks to months.
SourceAvutometinib Phase 2 Est. Readout (CHAMELEON)
Estimated primary completion for Avutometinib trial (NCT06394804) in Low-Grade Serous Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourceLetrozole Phase 2 Est. Readout (CHAMELEON)
Estimated primary completion for Letrozole trial (NCT06394804) in Low-Grade Serous Ovarian Cancer. Topline data typically follows completion by weeks to months.
SourceVS-7375 Phase 2 Est. Readout
Estimated primary completion for VS-7375 trial (NCT07659782) in Non-Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.
Sourcepanitumumab Phase 2 Est. Readout (TARGET-D 203)
Estimated primary completion for panitumumab trial (NCT07659795) in Colorectal Cancer. Topline data typically follows completion by weeks to months.
SourceAvutometinib Phase 2 Est. Readout
Estimated primary completion for Avutometinib trial (NCT06007924) in Thyroid Cancer. Topline data typically follows completion by weeks to months.
SourceHow VSTM's past catalysts played out
Market Overview
Stock performance and key metrics
Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
Websiteavutometinib
Low Grade Serous Ovarian Cancer
Defactinib
Pancreatic Adenocarcinoma
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
KRAS Activating Mutation
Avutometinib (VS-6766) + Defactinib (VS-6063)
Low Grade Serous Ovarian Cancer
defactinib (VS-6063)
Non Small Cell Lung Cancer
avutometinib (VS-6766) and adagrasib
Non Small Cell Lung Cancer
avutometinib and sotorasib
Non Small Cell Lung Cancer
avutometinib (VS-6766) and Defactinib
Non Small Cell Lung Cancer
panitumumab
Colorectal Cancer
cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)
Pancreatic Ductal Adenocarcinoma (PDAC)
Duvelisib
COVID-19
VS-6766
Breast Cancer
Avutometinib (VS-6766) + defactinib
Endometrioid Cancer
Encorafenib
Cutaneous Melanoma
Letrozole
Low-Grade Serous Ovarian Cancer
Cetuximab + mFOLFOX6
Colorectal Cancer
VS-7375
Pancreatic Ductal Adenocarcinoma
avutometinib and sotorasib and defactinib
Non Small Cell Lung Cancer
avutometinib (VS-6766)
Low Grade Ovarian Serous Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
avutometinib | Phase 3 | Low Grade Serous Ovarian Cancer | - | - |
Defactinib | Phase 3 | Pancreatic Adenocarcinoma | - | - |
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel | Phase 2 | KRAS Activating Mutation | - | - |
Avutometinib (VS-6766) + Defactinib (VS-6063) | Phase 2 | Low Grade Serous Ovarian Cancer | - | - |
defactinib (VS-6063) | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib (VS-6766) and adagrasib | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib and sotorasib | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib (VS-6766) and Defactinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
panitumumab | Phase 2 | Colorectal Cancer | - | - |
cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
Duvelisib | Phase 2 | COVID-19 | - | - |
VS-6766 | Phase 2 | Breast Cancer | - | - |
Avutometinib (VS-6766) + defactinib | Phase 2 | Endometrioid Cancer | - | - |
Encorafenib | Phase 2 | Cutaneous Melanoma | - | - |
Letrozole | Phase 2 | Low-Grade Serous Ovarian Cancer | - | - |
Cetuximab + mFOLFOX6 | Phase 2 | Colorectal Cancer | - | - |
VS-7375 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
avutometinib and sotorasib and defactinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib (VS-6766) | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Verastem, Inc.'s drug pipeline?→
CatalystAlert tracks 19 drug candidates in Verastem, Inc.'s (VSTM) pipeline across Phase 3, Phase 2. Its lead program is avutometinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Verastem, Inc.'s next FDA catalyst?→
Verastem, Inc.'s (VSTM) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VSTM biotech catalysts?→
Add VSTM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Verastem, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.